{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:54:27Z","timestamp":1768319667821,"version":"3.49.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/02\/0073"],"award-info":[{"award-number":["CB06\/02\/0073"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI18\/00244"],"award-info":[{"award-number":["FI18\/00244"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01819"],"award-info":[{"award-number":["PI20\/01819"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","award":["IISP 59383"],"award-info":[{"award-number":["IISP 59383"]}],"id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","award":["IISP 60552"],"award-info":[{"award-number":["IISP 60552"]}],"id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013816","name":"Departament d'Empresa i Coneixement, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR01029"],"award-info":[{"award-number":["2021SGR01029"]}],"id":[{"id":"10.13039\/501100013816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013816","name":"Departament d'Empresa i Coneixement, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR01354"],"award-info":[{"award-number":["2021SGR01354"]}],"id":[{"id":"10.13039\/501100013816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Human Papillomavirus (HPV) prophylactic vaccination has proven effective in preventing new infections, but it does not treat existing HPV infections or associated diseases. Hence, there is still an important reservoir of HPV in adults, as vaccination programs are mainly focused on young women. The primary objective of this non-randomized, open-label trial is to evaluate if a 3-dose regimen of Gardasil-9 in HPV16\/18-positive women could reduce the infective capacity of their body fluids. We aim to assess if vaccine-induced antibodies could neutralize virions present in the mucosa, thus preventing the release of infective particles and HPV transmission to sexual partners. As our main endpoint, the E1^E4-HaCaT model will be used to assess the infectivity rate of cervical, anal and oral samples, obtained from women before and after vaccination. HPV DNA positivity, virion production, seroconversion, and the presence of antibodies in the exudates, will be evaluated to attribute infectivity reduction to vaccination. Our study will recruit two different cohorts (RIFT-HPV1 and RIFT-HPV2) of non-vaccinated adult women. RIFT-HPV1 will include subjects with an HPV16\/18 positive cervical test and no apparent cervical lesions or cervical lesions eligible for conservative treatment. RIFT-HPV2 will include subjects with an HPV16\/18 positive anal test and no apparent anal lesions or anal lesions eligible for conservative treatment, as well as women with an HPV16\/18 positive cervical test and HPV-associated vulvar lesions. Subjects complying with inclusion criteria for both cohorts will be recruited to the main cohort, RIFT-HPV1. Three doses of Gardasil-9 will be administered intramuscularly at visit 1 (0 months), visit 2 (2 months) and visit 3 (6 months). Even though prophylactic HPV vaccines would not eliminate a pre-existing infection, our results will determine if HPV vaccination could be considered as a new complementary strategy to prevent HPV-associated diseases by reducing viral spread.<\/jats:p>\n<jats:p><jats:bold>Trial registration<\/jats:bold>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05334706\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05334706<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pone.0304080","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:44:34Z","timestamp":1716227074000},"page":"e0304080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the reduction of viral infectivity in HPV16\/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-700X","authenticated-orcid":true,"given":"Victoria","family":"L\u00f3pez-Codony","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"de Andr\u00e9s-Pablo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Ferrando-D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eul\u00e0lia","family":"Fern\u00e1ndez-Montol\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-7652","authenticated-orcid":true,"given":"Marta","family":"L\u00f3pez-Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-7092","authenticated-orcid":true,"given":"Sara","family":"Tous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Ortega-Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Torrej\u00f3n-Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-7353","authenticated-orcid":true,"given":"Anna","family":"Ferrer-Artola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-6896","authenticated-orcid":true,"given":"Josep Maria","family":"Sole-Sedeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blas","family":"Rup\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Saumoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1725","authenticated-orcid":true,"given":"Paula","family":"Peremiquel-Trillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-5329","authenticated-orcid":true,"given":"Miquel Angel","family":"Pav\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"pone.0304080.ref001","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.552028","article-title":"Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.","volume":"8","author":"AJ Kombe Kombe","year":"2021","journal-title":"Front Public Health"},{"issue":"2","key":"pone.0304080.ref002","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.","volume":"11","author":"D Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"pone.0304080.ref003","unstructured":"European Medicines Agency. Gardasil 9\u2014Product Information [Internet]. 2018 [cited 2023 Mar 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil-9."},{"key":"pone.0304080.ref004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer.","author":"RBS Roden","year":"2018","journal-title":"18, Nature Reviews Cancer. Nature Publishing Group"},{"key":"pone.0304080.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/157895","article-title":"Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.","volume":"2014","author":"PJ Klasse","year":"2014","journal-title":"Adv Biol."},{"issue":"46","key":"pone.0304080.ref006","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21).","volume":"107","author":"DL Mallery","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0304080.ref007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vaccine.2013.10.001","article-title":"Comprehensive Control of Human Papillomavirus Infections and Related Diseases.","volume":"31","author":"FX Bosch","year":"2013","journal-title":"Vaccine"},{"key":"pone.0304080.ref008","first-page":"119","volume-title":"Nature Reviews Clinical Oncology","author":"FX Bosch","year":"2016"},{"issue":"1","key":"pone.0304080.ref009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age.","volume":"105","author":"X Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"29\u201330","key":"pone.0304080.ref010","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"TJ Kemp","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"pone.0304080.ref011","first-page":"399","article-title":"Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions","volume":"11","author":"PE Castle","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"12","key":"pone.0304080.ref012","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine.","volume":"6","author":"TF Schwarz","year":"2010","journal-title":"Hum Vaccin"},{"issue":"19","key":"pone.0304080.ref013","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2018.03.034","article-title":"Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel\u00ae sponges","volume":"36","author":"KH Parker","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"pone.0304080.ref014","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/315364","article-title":"Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.","volume":"181","author":"ME Hagensee","year":"2000","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0304080.ref015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ijc.2910430109","article-title":"Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia","volume":"43","author":"L Dillner","year":"1989","journal-title":"Int J Cancer"},{"key":"pone.0304080.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.34.12.3056-3062.1996","article-title":"Cervical Mucus Antibodies against Human Papillomavirus Type 16, 18, and 33 Capsids in Relation to Presence of Viral DNA [Internet].","volume":"34","author":"Z Wang","year":"1996","journal-title":"JOURNAL OF CLINICAL MICROBIOLOGY"},{"key":"pone.0304080.ref017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jviromet.2019.04.007","article-title":"Comparison of multiplex-serology and ELISA based methods in detecting HPV16 L1 antibody responses in paired saliva and serum samples of healthy men","volume":"270","author":"V Loimaranta","year":"2019","journal-title":"J Virol Methods"},{"issue":"3","key":"pone.0304080.ref018","first-page":"431","article-title":"Chaturvedi AK, Hagensee ME. Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals","volume":"10","author":"JE Cameron","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"pone.0304080.ref019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcv.2019.05.004","article-title":"First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions.","volume":"117","author":"S Van Keer","year":"2019","journal-title":"J Clin Virol"},{"key":"pone.0304080.ref020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01657","article-title":"Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine.","volume":"11","author":"J Pattyn","year":"2020","journal-title":"Front Immunol."},{"key":"pone.0304080.ref021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijid.2019.09.006","article-title":"HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission","volume":"88","author":"A Vorsters","year":"2019","journal-title":"International Journal of Infectious Diseases"},{"issue":"4","key":"pone.0304080.ref022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","article-title":"Delivering on the promise: HPV vaccines and cervical cancer","volume":"2","author":"JT Schiller","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"pone.0304080.ref023","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1158\/1055-9965.EPI-19-0618","article-title":"Vaccination of young women decreases human papillomavirus transmission in heterosexual couples: Findings from the HITCH cohort study","volume":"28","author":"MD Wissing","year":"2019","journal-title":"Cancer Epidemiology Biomarkers and Prevention"},{"issue":"1","key":"pone.0304080.ref024","doi-asserted-by":"crossref","first-page":"e11284","DOI":"10.2196\/11284","article-title":"Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals.","volume":"8","author":"M El-Zein","year":"2019","journal-title":"JMIR Res Protoc [Internet]."},{"issue":"8","key":"pone.0304080.ref025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039383","article-title":"Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: A randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples.","volume":"10","author":"A Maccosham","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0304080.ref026","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/OLQ.0000000000001620","article-title":"Protection to Self and to One\u2019s Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study.","volume":"49","author":"A MacCosham","year":"2022","journal-title":"Sex Transm Dis."},{"issue":"1\u20132","key":"pone.0304080.ref027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.07.008","article-title":"The E4 protein; structure, function and patterns of expression","volume":"445","author":"J. Doorbar","year":"2013","journal-title":"Virology"},{"key":"pone.0304080.ref028","first-page":"166","volume-title":"Journal of Pathology","author":"J. Doorbar","year":"2016"},{"issue":"11","key":"pone.0304080.ref029","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1128\/JVI.79.11.6838-6847.2005","article-title":"Human Papillomavirus Type 31b Infection of Human Keratinocytes Does Not Require Heparan Sulfate","volume":"79","author":"NA Patterson","year":"2005","journal-title":"J Virol"},{"key":"pone.0304080.ref030","doi-asserted-by":"crossref","DOI":"10.1099\/0022-1317-83-11-2753","article-title":"Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line.","volume":"83","author":"MA Ozbun","year":"2002","journal-title":"Journal of General Virology"},{"issue":"12","key":"pone.0304080.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/v9120385","article-title":"Mutations in HPV18 E1\u02c6E4 impact virus capsid assembly, infectivity competence, and maturation.","volume":"9","author":"J Biryukov","year":"2017","journal-title":"Viruses."},{"key":"pone.0304080.ref032","doi-asserted-by":"crossref","first-page":"103165","DOI":"10.1016\/j.ebiom.2020.103165","article-title":"Infectious titres of human papillomaviruses (HPVs) in patient lesions, methodological considerations in evaluating HPV infectivity and implications for the efficacy of high-level disinfectants.","volume":"63","author":"MA Ozbun","year":"2021","journal-title":"EBioMedicine."},{"issue":"4","key":"pone.0304080.ref033","first-page":"213","article-title":"Electron microscopic detection of human papillomavirus particles in oral proliferative lesions.","volume":"30","author":"G Broich","year":"1989","journal-title":"Bull Tokyo Dent Coll [Internet]."},{"issue":"1","key":"pone.0304080.ref034","first-page":"53","article-title":"Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol","volume":"23","author":"E Hills","year":"1979","journal-title":"Internet]"},{"key":"pone.0304080.ref035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/CVI.00348-09","article-title":"Multiplexed Serologic Assay for Nine Anogenital Human Papillomavirus Types.","volume":"17","author":"DW Opalka","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"key":"pone.0304080.ref036","author":"Agencia Estatal Bolet\u00edn Oficial del Estado","journal-title":"BOE-A-2015-14082 Real Decreto 1090\/2015, de 4 de diciembre, por el que se regulan los ensayos cl\u00ednicos con medicamentos, los Comit\u00e9s de \u00c9tica de la Investigaci\u00f3n con medicamentos y el Registro Espa\u00f1ol de Estudios Cl\u00ednicos"},{"key":"pone.0304080.ref037","author":"European Medicines Agency.","year":"2018","journal-title":"ICH E6 (R2) Good clinical practice\u2014Scientific guideline [Internet]."},{"key":"pone.0304080.ref038","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","author":"C Patel","year":"2018","journal-title":"Eurosurveillance"},{"issue":"29","key":"pone.0304080.ref039","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.vaccine.2019.04.099","article-title":"Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination","volume":"37","author":"LE Markowitz","year":"2019","journal-title":"Vaccine"},{"issue":"10197","key":"pone.0304080.ref040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"M Drolet","year":"2019","journal-title":"The Lancet"},{"issue":"5","key":"pone.0304080.ref041","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciaa1770","article-title":"Population Impact of Girls-Only Human Papillomavirus 16\/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects","volume":"72","author":"J Hoes","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"pone.0304080.ref042","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14760584.2018.1471986","article-title":"Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.","volume":"17","author":"T Malag\u00f3n","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"37","key":"pone.0304080.ref043","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1016\/j.vaccine.2023.07.031","article-title":"Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals","volume":"41","author":"S Nyg\u00e5rd","year":"2023","journal-title":"Vaccine"},{"key":"pone.0304080.ref044","doi-asserted-by":"crossref","first-page":"106166","DOI":"10.1016\/j.ypmed.2020.106166","article-title":"Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.","volume":"138","author":"M Brotons","year":"2020","journal-title":"Prev Med (Baltim) [Internet]."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:45:14Z","timestamp":1716227114000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304080"}},"subtitle":[],"editor":[{"given":"Diane M.","family":"Harper","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304080","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}